Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing

SOUTH SAN FRANCISCO Calif. July 25 2017 PRNewswire Kezar Life Sciences a private clinicalstage biopharmaceutical company developing novel small molecule therapeutics targeting the immunoproteasome and the protein secretion pathway announced today that it ...